Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China
publication date: Mar 30, 2022
Beijing’s Brii Bio partnered with Sinopharm Holding to distribute Brii’s COVID neutralizing mAb therapy in China. The therapy was developed by combining non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients. In late 2021, it was approved in China for adults and pediatric patients with mild COVID-19 at high risk for progression to severe disease. Brii is a China-US company that develops therapies for infectious diseases such as hepatitis B virus (HBV), HIV, resistant gram-negative infections, and other conditions including CNS diseases. More details...
Stock Symbol: (HK: 2137)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.